This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALXN vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. TECH: Which Stock Is the Better Value Option?
AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS
by Zacks Equity Research
The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.
Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag
by Zacks Equity Research
The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.
Moderna Soars on Inclusion to S&P 500: ETFs in Focus
by Sanghamitra Saha
Moderna, known for its success in the COVID-19 vaccine, has entered the big league with its addition to the S&P 500 Index.
Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study
by Zacks Equity Research
Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.
Is a Beat in the Cards for Anthem (ANTM) in Q2 Earnings?
by Zacks Equity Research
Anthem's (ANTM) second-quarter results are likely to benefit on the back of higher premiums coupled with growing Medicaid and Medicare membership, partly offset by escalating costs.
Moderna (MRNA) Set to Join S&P 500 Riding on Vaccine Success
by Zacks Equity Research
Moderna's (MRNA) success with its COVID-19 vaccine, mRNA-1273, continues to drive the stock. The company crosses $100-billion in market capitalization and will join the S&P 500 soon.
Galapagos (GLPG) Falls on Inflammatory Study Data Readout
by Zacks Equity Research
Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.
Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is Why Growth Investors Should Buy Alexion (ALXN) Now
by Zacks Equity Research
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
AstraZeneca (AZN) Gets Clearance in UK for Alexion Acquisition
by Zacks Equity Research
AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.
Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug
by Zacks Equity Research
Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.
Alexion (ALXN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Alexion (ALXN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
7 Low Price-to-Book Stocks Worth Buying in July
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition
by Zacks Equity Research
AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.
ALXN or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. GMAB: Which Stock Is the Better Value Option?
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.
Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids
by Zacks Equity Research
The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.
Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Immunovant's (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401. Stock falls.
Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study
by Zacks Equity Research
Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.
Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug
by Zacks Equity Research
Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod
by Zacks Equity Research
The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.